Thermo Fisher Launches New High-Throughput, Fully Automated, Real-Time PCR Solution for COVID-19 Testing
By HospiMedica International staff writers Posted on 06 Aug 2020 |
Image: Amplitude Solution (Photo courtesy of Thermo Fisher Scientific Inc.)
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has introduced a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing.
The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school. The Thermo Fisher Scientific Amplitude Solution is a molecular diagnostic testing system that leverages the company's Applied Biosystems QuantStudio 7 Flex Real-time PCR instruments along with liquid handling products from Tecan Group. The modular solution delivers test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources.
The Amplitude Solution utilizes Thermo Fisher's Applied Biosystems TaqPath COVID-19 Combo Kit, a fast, highly sensitive multiplex diagnostic test that contains the assays and controls needed for the qualitative detection of nucleic acid from SARS-CoV-2. As part of this offering, Amplitude Solution customers will enter into a supply agreement with Thermo Fisher to secure an up-front, confirmed and reliable supply of reagents and consumables. Backed by dedicated, 24/7 customer support from Thermo Fisher, the end-to-end solution, including the reagents, consumables and test kits, is available from a single source. The company will submit this new end-to-end solution to the US Food and Drug Administration for Emergency Use Authorization (EUA) and plans to secure additional authorizations globally.
"Increased testing capability is an essential part of any community's plan to reopen schools and businesses," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Current approaches to scale up testing require substantial resources and personnel. This more automated, high-throughput solution will enable laboratories around the world to increase testing volumes and help the public get their test results faster."
The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school. The Thermo Fisher Scientific Amplitude Solution is a molecular diagnostic testing system that leverages the company's Applied Biosystems QuantStudio 7 Flex Real-time PCR instruments along with liquid handling products from Tecan Group. The modular solution delivers test results in a four-step process requiring minimal hands-on time, laboratory space and staffing resources.
The Amplitude Solution utilizes Thermo Fisher's Applied Biosystems TaqPath COVID-19 Combo Kit, a fast, highly sensitive multiplex diagnostic test that contains the assays and controls needed for the qualitative detection of nucleic acid from SARS-CoV-2. As part of this offering, Amplitude Solution customers will enter into a supply agreement with Thermo Fisher to secure an up-front, confirmed and reliable supply of reagents and consumables. Backed by dedicated, 24/7 customer support from Thermo Fisher, the end-to-end solution, including the reagents, consumables and test kits, is available from a single source. The company will submit this new end-to-end solution to the US Food and Drug Administration for Emergency Use Authorization (EUA) and plans to secure additional authorizations globally.
"Increased testing capability is an essential part of any community's plan to reopen schools and businesses," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Current approaches to scale up testing require substantial resources and personnel. This more automated, high-throughput solution will enable laboratories around the world to increase testing volumes and help the public get their test results faster."
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans